Fulcrum Therapeutics (FULC) Return on Capital Employed: 2020-2025
Historic Return on Capital Employed for Fulcrum Therapeutics (FULC) over the last 4 years, with Sep 2025 value amounting to -0.41%.
- Fulcrum Therapeutics' Return on Capital Employed fell 30.00% to -0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.41%, marking a year-over-year decrease of 30.00%. This contributed to the annual value of -0.09% for FY2024, which is 40.00% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Return on Capital Employed stood at -0.41% for Q3 2025, which was down 651.23% from -0.05% recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year Return on Capital Employed high stood at -0.05% for Q2 2025, and its period low was -0.59% during Q2 2021.
- Its 3-year average for Return on Capital Employed is -0.29%, with a median of -0.38% in 2023.
- Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 35bps in 2024, then declined by 30bps in 2025.
- Over the past 5 years, Fulcrum Therapeutics' Return on Capital Employed (Quarterly) stood at -0.36% in 2021, then decreased by 15bps to -0.51% in 2022, then rose by 8bps to -0.43% in 2023, then soared by 35bps to -0.08% in 2024, then fell by 30bps to -0.41% in 2025.
- Its Return on Capital Employed stands at -0.41% for Q3 2025, versus -0.05% for Q2 2025 and -0.08% for Q4 2024.